337 related articles for article (PubMed ID: 18175266)
1. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
[TBL] [Abstract][Full Text] [Related]
2. Approaches for minimizing metabolic activation of new drug candidates in drug discovery.
Kumar S; Mitra K; Kassahun K; Baillie TA
Handb Exp Pharmacol; 2010; (196):511-44. PubMed ID: 20020275
[TBL] [Abstract][Full Text] [Related]
3. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
Baillie TA
Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955
[TBL] [Abstract][Full Text] [Related]
4. Minimizing the potential for metabolic activation as an integral part of drug design.
Evans DC; Baillie TA
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
[TBL] [Abstract][Full Text] [Related]
5. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
6. Strategies for dealing with metabolite elucidation in drug discovery and development.
Nassar AE; Talaat RE
Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
[TBL] [Abstract][Full Text] [Related]
7. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry.
Ma S; Subramanian R
J Mass Spectrom; 2006 Sep; 41(9):1121-39. PubMed ID: 16967439
[TBL] [Abstract][Full Text] [Related]
8. Application of pharmaceutical profiling assays for optimization of drug-like properties.
Di L; Kerns EH
Curr Opin Drug Discov Devel; 2005 Jul; 8(4):495-504. PubMed ID: 16022186
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
Baillie TA
Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
[TBL] [Abstract][Full Text] [Related]
10. Modeling promiscuity based on in vitro safety pharmacology profiling data.
Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
[TBL] [Abstract][Full Text] [Related]
11. Lead optimization strategies as part of a drug metabolism environment.
Korfmacher WA
Curr Opin Drug Discov Devel; 2003 Jul; 6(4):481-5. PubMed ID: 12951811
[TBL] [Abstract][Full Text] [Related]
12. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
Evans DC; Watt AP; Nicoll-Griffith DA; Baillie TA
Chem Res Toxicol; 2004 Jan; 17(1):3-16. PubMed ID: 14727914
[TBL] [Abstract][Full Text] [Related]
13. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds.
Waring JF; Anderson MG
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):59-65. PubMed ID: 15679173
[TBL] [Abstract][Full Text] [Related]
14. Toxicophores: groups and metabolic routes associated with increased safety risk.
Williams DP; Naisbitt DJ
Curr Opin Drug Discov Devel; 2002 Jan; 5(1):104-15. PubMed ID: 11865664
[TBL] [Abstract][Full Text] [Related]
15. Investigation of toxic metabolites during drug development.
Park K; Williams DP; Naisbitt DJ; Kitteringham NR; Pirmohamed M
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):425-34. PubMed ID: 15996699
[TBL] [Abstract][Full Text] [Related]
16. Idiosyncratic drug reactions: past, present, and future.
Uetrecht J
Chem Res Toxicol; 2008 Jan; 21(1):84-92. PubMed ID: 18052104
[TBL] [Abstract][Full Text] [Related]
17. Safety assessment of drug metabolites: Characterization of chemically stable metabolites.
Humphreys WG; Unger SE
Chem Res Toxicol; 2006 Dec; 19(12):1564-9. PubMed ID: 17173369
[TBL] [Abstract][Full Text] [Related]
18. [Crucial tasks of pharmacologists of the USSR in accelerating scientific and technological progress].
Val'dman AV
Farmakol Toksikol; 1986; 49(6):5-15. PubMed ID: 3817145
[No Abstract] [Full Text] [Related]
19. Putting nature back into drug discovery.
Müller-Kuhrt L
Nat Biotechnol; 2003 Jun; 21(6):602. PubMed ID: 12776140
[No Abstract] [Full Text] [Related]
20. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
